Initial experience with simultaneous 18F-FDG PET/MRI in the evaluation of cardiac sarcoidosis and myocarditis

Clinical Nuclear Medicine

Volumn 42, Issue 7, 2017, Pages e328-e334

  Hanneman, Kate ^a,b   Kadoch, Michael ^b   Guo, Henry H ^c   Jamali, Mehran ^c   Quon, Andrew ^c   Iagaru, Andrei ^c   Herfkens, Robert ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b Department of Radiology ^*  (Canada)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac sarcoid; PET; PET MRI

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CARDIAC SARCOIDOSIS; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ELECTROCARDIOGRAPHY; FEASIBILITY STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; IMAGE QUALITY; INTERMETHOD COMPARISON; MALE; MIDDLE AGED; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION EXPOSURE; AGED; DIAGNOSTIC IMAGING; IMAGE PROCESSING; MULTIMODAL IMAGING; SARCOIDOSIS;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIMODAL IMAGING; MYOCARDITIS; POSITRON-EMISSION TOMOGRAPHY; SARCOIDOSIS;

EID: 85017646022     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0000000000001669     Document Type: Article

References (39)

1. Rybicki BA, Major M, Popovich J Jr, et al. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol. 1997;145:234-241.
2. Perry A, Vuitch F. Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 1995;119:167-172.
3. Vignaux O. Cardiac sarcoidosis: spectrum of MRI features. AJR Am J Roentgenol. 2005;184:249-254.
4. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation. 2009;120:1969-1977.
5. Vignaux O, Dhote R, Duboc D, et al. Detection ofmyocardial involvement in patients with sarcoidosis applying T2-weighted, contrast-enhanced, and cine magnetic resonance imaging: initial results of a prospective study. J Comput Assist Tomogr. 2002;26:762-767.
6. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol. 2005;45:1683-1690.
7. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329-336.
8. Skali H, Schulman AR, Dorbala S. (18)F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep. 2013;15:352.
9. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241-248.
10. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J NuclMed. 2004;45:1989-1998.
11. White JA, Rajchl M, Butler J, et al. Active cardiac sarcoidosis: first clinical experience of simultaneous positron emission tomography-magnetic resonance imaging for the diagnosis of cardiac disease. Circulation. 2013;127: e639-e641.
12. Schneider S, Batrice A, Rischpler C, et al. Utility of multimodal cardiac imaging with PET/MRI in cardiac sarcoidosis: implications for diagnosis, monitoring and treatment. Eur Heart J. 2014;35:312.
13. Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013;34:2636-2648.
14. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305-1323.
15. Williams G, Kolodny GM. Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR Am J Roentgenol. 2008;190:W151-W156.
16. McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108:54-59.
17. Shrimpton P, Hillier MC, Lewis MA, et al. Doses From Computed Tomography (CT) Examinations in the UK: 2003 Review. Chilton, UK: National Radiological Protection Board; 2005.
18. Stabin MG. Radiopharmaceuticals for nuclear cardiology: radiation dosimetry, uncertainties, and risk. J Nucl Med. 2008;49:1555-1563.
19. Schlosser T, Nensa F, Mahabadi AA, et al. Hybrid MRI/PET of the heart: a new complementary imaging technique for simultaneous acquisition of MRI and PET data. Heart. 2013;99:351-352.
20. Nensa F, Poeppel TD, Beiderwellen K, et al. Hybrid PET/MR imaging of the heart: feasibility and initial results. Radiology. 2013;268:366-373.
21. Pellegrino D, Bonab AA, Dragotakes SC, et al. Inflammation and infection: imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG. J NuclMed. 2005;46:1522-1530.
22. Beaulieu S, Kinahan P, Tseng J, et al. SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences. J Nucl Med. 2003;44:1044-1050.
23. Graham MM, Badawi RD, Wahl RL. Variations in PET/CTmethodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey. J Nucl Med. 2011;52:311-317.
24. Houshmand S, Salavati A, Segtnan EA, et al. Dual-time-point imaging and delayed-time-point fluorodeoxyglucose-PET/computed tomography imaging in various clinical settings. PET Clin. 2016;11:65-84.
25. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med. 2001;42:1412-1417.
26. Roncali E, Cherry SR. Application of silicon photomultipliers to positron emission tomography. Ann Biomed Eng. 2011;39:1358-1377.
27. Yeom JY, Vinke R, Levin CS. Optimizing timing performance of silicon photomultiplier-based scintillation detectors. Phys Med Biol. 2013;58: 1207-1220.
28. Minamimoto R, Levin C, Jamali M, et al. Improvements in PET Image Quality in Time of Flight (TOF) Simultaneous PET/MRI. Mol Imaging Biol. 2016;18:776-781.
29. Maron MS. Contrast-enhanced CMR in HCM: what lies behind the bright light of LGE and why it now matters. JACC Cardiovasc Imaging. 2013;6: 597-599.
30. Moravsky G, Ofek E, Rakowski H, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging. 2013;6:587-596.
31. Serra JJ, Monte GU, Mello ES, et al. Images in cardiovascularmedicine. Cardiac sarcoidosis evaluated by delayed-enhanced magnetic resonance imaging. Circulation. 2003;107:e188-e189.
32. Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med. 2003;44:1030-1036.
33. Hoey ET, Gulati GS, Ganeshan A, et al. CardiovascularMRI for assessment of infectious and inflammatory conditions of the heart. AJR Am J Roentgenol. 2011;197:103-112.
34. Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53: 1475-1487.
35. Crouser ED, Ono C, Tran T, et al. Improved detection of cardiac sarcoidosis using magnetic resonance with myocardial T2 mapping. Am J Respir Crit Care Med. 2014;189:109-112.
36. Hulten E, Aslam S, Osborne M, et al. Cardiac sarcoidosis - state of the art review. Cardiovasc Diagn Ther. 2016;6:50-63.
37. Friedrich MG, Marcotte F. Cardiac magnetic resonance assessment of myocarditis. Circ Cardiovasc Imaging. 2013;6:833-839.
38. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am JMed. 1977;63:86-108.
39. Thompson HM, Minamimoto R, Jamali M, et al. A prospective, matched comparison study of SUV measurements from time-of-flight versus nontime- of-flight PET/CT scanners. Clin Nucl Med. 2016;41:e323-e326.